Understanding PLZF: Two Transcriptional Targets, REDD1 and Smooth Muscle α-actin, Define New Questions in Growth Control, Senescence, Self-renewal and Tumor Suppression

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2011 Feb 12

PMID 21311223

Citations 15

Authors

Marina Kolesnichenko

Peter K Vogt

Affiliations

Soon will be listed here.

Abstract

PLZF can function as a transcriptional activator or as a transcriptional repressor. Recent studies have identified two direct transcriptional targets of PLZF, REDD1 and smooth muscle α-actin. REDD1 is activated by PLZF. It mediates the PLZF-dependent downregulation of TORC1 and is responsible for the maintenance of pluripotency in cultures of spermatogonial progenitor cells. This activity may extend to other stem-like cell types. The effect of REDD1 on TORC1 also raises the possibility that REDD1 controls cell growth, tumorigenicity and senescence. The regulatory loop extending from PLZF via REDD1 to TORC1 identifies REDD1 as a critical determinant of TOR activity. The transcription of smooth muscle α-actin is repressed by PLZF. In fibroblasts, this downregulation is accompanied by a change of cell shape and a dramatic reorganization of the cytoskeleton. It is also correlated with the acquisition of cellular resistance to oncogenic transformation. The resistance is selective, it works against some oncoproteins but not against others. The molecular mechanisms underlying the changes in the cytoskeleton and in the susceptibility to oncogenic transformation are unknown. However these changes are dependent on the activity of RAS and thus probably involve the RAC/RHO family of proteins.

Citing Articles

The Role of Plzf in Spermatogonial Stem Cell Maintenance and Differentiation: Mapping the Transcriptional Dynamics and Key Interactions.

Ghasemi N, Azizi H, Razavi-Amoli S, Skutella T Cells. 2024; 13(23).

PMID: 39682679 PMC: 11640652. DOI: 10.3390/cells13231930.

knockdown induces cell cycle arrest and apoptosis in breast cancer cells through the ZBTB16/ANXA7/Cyclin B1 axis.

Liu D, Du Q, Zhu Y, Guo Y, Guo Y Acta Biochim Biophys Sin (Shanghai). 2024; .

PMID: 39308302 PMC: 11659777. DOI: 10.3724/abbs.2024148.

The effects of vitamin E supplementation on sperm parameters, chromatin integrity, and gene expression before and after freezing in aged mice.

Zarei S, Molavi F, Abasnezhad F, Majidi B, Mohammadihosseinabad S, Ranjbar F Clin Exp Reprod Med. 2024; 51(3):213-224.

PMID: 38853131 PMC: 11372309. DOI: 10.5653/cerm.2023.06632.

The Role of Promyelocytic Leukemia Zinc Finger (PLZF) and Glial-Derived Neurotrophic Factor Family Receptor Alpha 1 (GFRα1) in the Cryopreservation of Spermatogonia Stem Cells.

Shamhari A, Jefferi N, Abd Hamid Z, Budin S, Idris M, Taib I Int J Mol Sci. 2023; 24(3).

PMID: 36768269 PMC: 9915902. DOI: 10.3390/ijms24031945.

The Enigmas of Lymphatic Muscle Cells: Where Do They Come From, How Are They Maintained, and Can They Regenerate?.

Kenney H, Peng Y, Bentley K, Xing L, Ritchlin C, Schwarz E Curr Rheumatol Rev. 2023; 19(3):246-259.

PMID: 36705238 PMC: 10257750. DOI: 10.2174/1573397119666230127144711.

References

Choo A, Blenis J . Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle. 2009; 8(4):567-72. DOI: 10.4161/cc.8.4.7659. View

Harrison D, Strong R, Sharp Z, Nelson J, Astle C, Flurkey K . Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009; 460(7253):392-5. PMC: 2786175. DOI: 10.1038/nature08221. View

Schwarzer R, Tondera D, Arnold W, Giese K, Klippel A, Kaufmann J . REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene. 2004; 24(7):1138-49. DOI: 10.1038/sj.onc.1208236. View

Xu D, Holko M, Sadler A, Scott B, Higashiyama S, Berkofsky-Fessler W . Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity. Immunity. 2009; 30(6):802-16. PMC: 2711215. DOI: 10.1016/j.immuni.2009.04.013. View

Hobbs R, Pandolfi P . Shape-shifting and tumor suppression by PLZF. Oncotarget. 2011; 1(1):3-5. PMC: 4053541. DOI: 10.18632/oncotarget.102. View

Barna M, Merghoub T, Costoya J, Ruggero D, Branford M, Bergia A . Plzf mediates transcriptional repression of HoxD gene expression through chromatin remodeling. Dev Cell. 2002; 3(4):499-510. DOI: 10.1016/s1534-5807(02)00289-7. View

OReilly K, Rojo F, She Q, Solit D, Mills G, Smith D . mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006; 66(3):1500-8. PMC: 3193604. DOI: 10.1158/0008-5472.CAN-05-2925. View

Fumarola C, La Monica S, Alfieri R, Borra E, Guidotti G . Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis. Cell Death Differ. 2005; 12(10):1344-57. DOI: 10.1038/sj.cdd.4401660. View

Labbaye C, Spinello I, Quaranta M, Pelosi E, Pasquini L, Petrucci E . A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol. 2008; 10(7):788-801. DOI: 10.1038/ncb1741. View

10.

Brugarolas J, Lei K, Hurley R, Manning B, Reiling J, Hafen E . Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004; 18(23):2893-904. PMC: 534650. DOI: 10.1101/gad.1256804. View

11.

Shi J, Sun M, Vogt P . Smooth muscle α-actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation. Oncotarget. 2010; 1(1):9-21. PMC: 2903758. DOI: 10.18632/oncotarget.104. View

12.

Cloughesy T, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S . Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008; 5(1):e8. PMC: 2211560. DOI: 10.1371/journal.pmed.0050008. View

13.

Costoya J, Hobbs R, Barna M, Cattoretti G, Manova K, Sukhwani M . Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet. 2004; 36(6):653-9. DOI: 10.1038/ng1367. View

14.

HARUTA T, Uno T, Kawahara J, Takano A, Egawa K, Sharma P . A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol. 2000; 14(6):783-94. DOI: 10.1210/mend.14.6.0446. View

15.

Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A . Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008; 118(9):3065-74. PMC: 2518073. DOI: 10.1172/JCI34739. View

16.

Dibble C, Asara J, Manning B . Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol. 2009; 29(21):5657-70. PMC: 2772744. DOI: 10.1128/MCB.00735-09. View

17.

Savage A, Constantinides M, Han J, Picard D, Martin E, Li B . The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity. 2008; 29(3):391-403. PMC: 2613001. DOI: 10.1016/j.immuni.2008.07.011. View

18.

Sun S, Rosenberg L, Wang X, Zhou Z, Yue P, Fu H . Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005; 65(16):7052-8. DOI: 10.1158/0008-5472.CAN-05-0917. View

19.

Hobbs R, Seandel M, Falciatori I, Rafii S, Pandolfi P . Plzf regulates germline progenitor self-renewal by opposing mTORC1. Cell. 2010; 142(3):468-79. PMC: 3210556. DOI: 10.1016/j.cell.2010.06.041. View

20.

Wan X, Harkavy B, Shen N, Grohar P, Helman L . Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2006; 26(13):1932-40. DOI: 10.1038/sj.onc.1209990. View